Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease,
and is characterized by liver inflammation and fat accumulation. Dietary interventions, such …

Background Non-alcoholic liver disease (NAFLD) is the hepatic manifestation of metabolic
syndrome, and it can progress to non-alcoholic steatohepatitis (NASH). Alterations in the gut …

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic
syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly …

Background Non-alcoholic fatty liver (NAFLD) is a common, multi-factorial, and poorly
understood liver disease whose incidence is globally rising. NAFLD is generally …

Liver fibrosis is one main histological characteristic of nonalcoholic steatohepatitis (NASH),
a disease paralleling a worldwide surge in metabolic syndromes with no approved …

Hepatic steatosis is a multifactorial condition that is often observed in obese patients and is
a prelude to non-alcoholic fatty liver disease. Here, we combine shotgun sequencing of fecal …

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity but also found in non-
obese individuals. Gut microbiome profiles of 171 Asians with biopsy-proven NAFLD and 31 …

Nonalcoholic fatty liver disease (NAFLD) is a prevalent and progressive disease spectrum
ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), yet …

Nonalcoholic steatohepatitis (NASH) has been linked with the gut-liver axis. Here, we
investigate the potential for repurposing disulfiram (DSF), a drug commonly used to treat …

The microbiota–gut–liver axis has emerged as an important player in developing
nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease (NAFLD) …